



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/720,326	12/22/2000	Koh Sato	04853.0052	9287

22852 7590 07/18/2005

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER  
LLP  
901 NEW YORK AVENUE, NW  
WASHINGTON, DC 20001-4413

EXAMINER

CANELLA, KAREN A

ART UNIT PAPER NUMBER

1643

DATE MAILED: 07/18/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

**Application No.**

09/720,326

**Applicant(s)**

SATO ET AL.

**Examiner**

Karen A. Canella

**Art Unit**

1643

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1,4,6,9-16,19-21 and 33-42 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,4,6,9-16,19-21 and 33-42 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |  |
|--|--|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. ____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)            |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date <u>5/20/2005</u> . | 6) <input type="checkbox"/> Other: ____  |

20

## **DETAILED ACTION**

### ***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on December 29, 2004 has been entered.

Claims 34-42 have been added. Claims 1, 4, 6, 9-16, 19-21, 33-42 are pending and under consideration.

Sections of Title 35, U.S. Code not found in this action can be found in a previous action.

The rejection of claims 1, 4, 9, 10, 12, 13-15, 19, 20 and 33 under 35 U.S.C. 103(a) as being unpatentable over Sager et al (US 5,494,806) in view of Potts (Diseases of the Parathyroid gland and other Hyper- and Hypocalcemic Disorders, In: Harrison's principles of Internal Medicine, 12th Edition, pages 1902-1915, IDS reference) and Schlom (In: Molecular foundations of Oncology, Samuel Broader, Ed, 1991, pages 95-134) is maintained for reasons of record. New claims 34-38, 40 and 41 are also rejected for the same reasons of record.

Claim 1 is drawn to a method of treating hypercalcemic crisis associated with malignant tumor comprising administering a humanized anti-PTH-rP antibody capable of inhibiting the binding between PTH-rP to a receptor thereof, decreasing and maintaining the blood calcium level by 1 mg/dl within 24 hours to effectively treat the patient and maintaining the at least 1 mg/dl decrease in blood calcium level over at least 24 hours, wherein said blood calcium level decreases to below 15 mg/dl. Claim 4 embodies the method of claim 1 wherein the humanized anti-PTHrP antibody is an antibody fragment capable of inhibiting the binding between PTHrP and a receptor thereof. Claim 9 embodies the method of claim 1 wherein the hypercalcemic crises is associated with at least one of coma or cardiac arrest. Claim 10 embodies the method of claim 1 or claim 4 wherein the antibody is bound to the carrier. Claim 12 embodies the method

Art Unit: 1643

of claim 4 fragment is Fab, scFv, F(ab')<sub>2</sub> or Fv. Claim 33 embodies the method of claim 1 wherein the blood calcium level is decreased by at least 2 mg/dl

Claim 13 is drawn to a method of treating hypercalcemic crisis associated with malignant tumor comprising administering a humanized anti-PTH-rP antibody capable of inhibiting the binding between PTH-rP to a receptor thereof; decreasing the blood calcium level to below 15 mg/dl to effectively treat the patient. Claim 14 embodies the method of claim 13 wherein the patient is administered at least one fragment of the humanized anti-PTHrP antibody. Claim 15 embodies the method of claim 14 wherein the fragment is Fab, scFv, F(ab')<sub>2</sub> or Fv. Claim 19 embodies the method of claim 13 wherein the hypercalcemic crises is associated with at least one of coma or cardiac arrest. Claim 20 embodies the method of claim 13 or 14, wherein the antibody is bound to a carrier.

Claim 34 is drawn to a method for treating hypercalcemic crisis associated with malignant tumor comprising administering to a patient a humanized anti-PHTrP antibody which inhibits the binding between PTHrP and the receptor thereof, allowing the antibody to inhibit the binding of PTHrP to the receptor, decreasing a blood calcium level to effectively treat the patient. Claim 35 embodies the method of claim 34 wherein the hypercalcemic crises is defined as a blood calcium level that does not normalize after 24 hours of treatment and remain normal over at least 24 hour with one of the therapeutic agents chosen from bisphosphonate, calcitonin, a steroid, phosphate buffer, physiological saline and furosemide. Claim 36 embodies the method of claim 35 wherein normal blood calcium level is less than 12 mg/dl. Claim 37 embodies the method of claim 34 wherein the patient is administered at least one fragment of the humanized anti-PTGrP antibody. Claim 38 embodies the method of claim 37 wherein said fragment is chosen from Fab, scFv, F(ab')<sub>2</sub>, and Fv. Claim 40 embodies the method of claim 34 wherein the hypercalcemic crisis is associated with at least one of coma or cardiac arrest. Claim 41 embodies the method of claim 34 or claim 37 wherein the antibody is bound by a carrier.

Seeger et al (U.S. 5,494,806) teach a method for rapidly intervening in a patient exhibiting hypercalcemia comprising the administration of antagonists of PTHrP (column 24, lines 35-41). Seeger et al teach that such antagonists include compounds which interfere with the PTH receptor-mediated activation and that the appropriate antibody antagonist or peptide antagonist is administered at a dosage that provides adequate competition for PTHrP binding to the PTH

Art Unit: 1643

receptor and that this will correspond to the dosage sufficient to lower the calcium level to below 10 mg/dl (column 24, lines 41-51), thus fulfilling the specific embodiment of treating a patient susceptible to hypercalcemic crisis associated with impaired consciousness comprising administering to said patient a anti-PTHrP antibody inhibiting the binding between PTHrP and the PTH receptor and allowing the antibody to inhibit the binding of PTHrP to the PTH receptor and decreasing a blood calcium level to effectively treat said patient. Seger et al teach that the antibody can be formulated in a carrier (column 24, lines 45-46) thus fulfilling the specific embodiment of claims 10 and 20. Seger et al teach that treatment may be repeated as necessary for long term maintenance of acceptable calcium levels of less than 10.1 mg/dl (column 24, lines 52-55) thus fulfilling the specific embodiment of claims 1 and 13 specifying that the blood calcium level be decreased to below 15 mg/dl. Seger et al teach that the antibodies and other compounds of the invention are useful for the treatment of disorders characterized by the interaction between a cell receptor of the invention and a ligand (column 23, lines 25-40). Seger et al teach that hypercalcemia mediated by PTHrP results from humoral hypercalcemia of malignancy (column 23, lines 46-47) thus fulfilling the specific embodiment of claims 1 and 13 drawn to a malignant tumor. Seger et al teach that compounds, including antibodies and polypeptide, may be screened for their agonistic or antagonistic properties using the cAMP accumulation, intracellular calcium, and/or inositol phosphate assays as specifically described (columns 22, line 65-column 23, line 22). Seger et al do not specifically teach administering a humanized anti-PTHrP antibody or the treatment of hypercalcemic crises wherein the patient exhibits at least one of coma or cardiac arrest.

Potts teaches that severe hypercalcemia, usually defined as 15 mg/dl or above is a medical emergency, and that coma or cardiac arrest can occur when serum calcium levels are at 15 to 18 mg/dl or higher. Thus, the art recognizes that severe hypercalcemia results in coma or cardiac arrest.

Schlom teaches that in all of the previous reported human trials in which non-immunosuppressed patients were treated with multiple doses of murine antibodies only the first and perhaps the second dose of said antibody was efficiently reaching the tumor site due to the HAMA response. Schlom teaches that it is unrealistic to assume that just one or two administrations of any anti-cancer therapeutic would be effective. Schlom teaches that the

Art Unit: 1643

answer to this problem is the humanization of the murine antibodies (pages 97-98, bridging paragraph). Schlom also teaches that F(ab')<sub>2</sub> or Fab' fragments also help reduce the HAMA response (page 119 second column, lines 16-17 under the heading "Single Chain Antigen Binding Proteins). Schlom also teaches that scFv although comparable in binding affinity to FAb' have a more rapid plasma clearance than the Fab' fragment resulting in a greater tumor to tissue ratio. Schlom also points out that the small size of the scFv improves the capacity for penetration through the tumor mass.. Schlom also points out that scFv are easier to make than F9ab')<sub>2</sub> of Fab' fragments.

It would have been prima facie obvious to one of ordinary skill in the art at the time the claimed invention was made to treat a patient undergoing hypercalcemic crisis wherein said crises was manifest by coma or cardiac arrest or blood calcium levels in excess of 15 mg/dl by the administration of a humanized anti-PTHrP antibody which is an antagonist of PTHrP binding to the PTH receptor in order to lower blood calcium to normal levels. One of ordinary skill in the art would have been motivated to do so with a reasonable expectation of success by the teachings of Seger et al on the method of treating patients needing immediate intervention because elevated serum calcium level can be fatal; and the teachings of Potts regarding the risk of coma or cardiac arrest in individual having serum calcium levels of 15 mg/dl to 18 mg/ dl or higher. It would also be obvious to use a fragment of the antibody such as scFv for maximum penetration into the tumor vasculature. Further, one of skill in the art would be motivated to maintain the decrease in blood calcium levels in order insure that the patient was stabilized. The difference between hypercalcemic crisis and hypercalcemia is only one of degree. In the case of the crisis the levels of calcium are such that cardiac arrest and coma are imminent. One of skill in the art would also be motivated to administered the claimed antibodies to a patient undergoing hypercalcemic crises in whom the conventional treatments listed in claim 35 have failed. One of skill in the art would want to try a new treatment which would act by a different molecular mechanism from that of the conventional treatments in order to prevent death from ensuing in the patient.

Art Unit: 1643

The rejection of claims 1, 4, 9-15, 19-21 and 33 under 35 U.S.C. 103(a) as being unpatentable over Seger et al (US 5,494,806) and Potts (Diseases of the Parathyroid gland and other Hyper- and Hypocalcemic Disorders, In: Harrison's principles of Internal Medicine, 12th Edition, pages 1902-1915) and Schlom (In: Molecular foundations of Oncology, Samuel Broader, Ed, 1991, pages 95-134). as applied to claims 1, 4, 9, 10, 12, 13-15, 19, 20 and 33-38, 40 and 41 above, and further in view of Gristina et al (5,681,565) is maintained for reasons of record. New claims 34-38, 40-42 are also rejected for the same reasons of record. The specific embodiments of claims 1, 4, 9, 10, 12, 13-15, 19, 20, 33-38, 40 and 41 and the teachings of Seger et al, Potts and Schlom which render obvious said embodiments are set forth above. None of the cited reference specifically teach the antibody bound to the carrier PEG.

Gristina et al teach that antibodies can administered in a cream or ointment carrier such as oleaginous bases or polyethylene glycol for in situ use (column 5, lines 3-21). It would have been prima facie obvious to one of ordinary skill in the art at the time the claimed invention to use PEG as a carrier. One of ordinary skill in the art would have been motivated to do so with a reasonable expectation of success by the teachings of Grishina et al on the effectiveness of PEG as a carrier for in situ administration of antibodies. The difference between hypercalcemic crisis and hypercalcemia is only one of degree. In the case of the crisis the levels of calcium are such that cardiac arrest and coma are imminent. One of skill in the art would also be motivated to administered the claimed antibodies to a patient undergoing hypercalceimic crises in whom the conventional treatments listed in claim 35 have failed. One of skill in the art would want to try a new treatment which would act by a different molecular mechanism from that of the conventional treatments in order to prevent death from ensuing in the patient.

The rejection of Claims 1, 6, 9, 10, 13, 16, 19, 20 and 33 under 35 U.S.C. 103(a) as being unpatentable over the abstract of Sato et al (WO 9813388, IDS reference) in view of Potts (Diseases of the Parathyroid gland and other Hyper- and Hypocalcemic Disorders, In: Harrison's principles of Internal Medicine, 12th Edition, pages 1902-1915) is maintained for reasons of record. Claims 34-36, 39, 40 and 41 are also rejected for the same reasons of record. The

Art Unit: 1643

specific embodiments of claims 1, 6, 9, 10, 13, 16, 19, 20 and 33-36, 40 and 41 are set forth above.

Claims 6 and 16 embody the methods of claim 1 and 13, respectively, wherein the antibody is humanized antibody deposited under the Accession Number FERM BP-5631. The specification teaches that the humanized monoclonal antibody #23-57-137-1 was deposited under the Accession Number FERM BP-5631. Claim 39 embodies the method of claim 34 wherein the humanized antibody is deposited under Accession No. FERM BP-5631.

The abstract of Sato et al teaches the humanized #23-57-137-1 monoclonal antibody. The abstract teaches that the humanized antibody can be used to treat hypercalcemia and other disorders caused by cancer. The abstract does not teach that the humanized #23-57-137-1 monoclonal antibody would inhibit the binding of the PTHrP and the PTH receptor, however, the antibody is identical to the specific embodiment of claims 6 and 16, therefore said antibody must have the inherent characteristic of inhibiting the binding of PTHrP to the PTH receptor. The abstract does not specifically teach drug-resistant hypercalcemic crisis associated with coma and cardiac arrest of a blood calcium level in excess of 15mg/dl.

Potts teaches that severe hypercalcemia, usually defined as 15 mg/dl or above is a medical emergency, and that coma or cardiac arrest can occur when serum calcium levels are at 15 to 18 mg/dl or higher. Potts teaches that the humoral mediator of malignancy associated hypercalcemia is PTHrP. Potts teaches that this mediator competes with PTH for occupancy of the PTH receptor and induces hypercalcemia in test animals, and that the data indicate that PTHrP acts through activation of the PTH receptor (page 1908, first column, lines 2-9).

It would have been prima facie obvious to one of ordinary skill in the art at the time the claimed invention to use the #23-57-137-1 antibody in the treatment of hypercalcemic crises. One of ordinary skill in the art would have been motivated to do so with a reasonable expectation of success by the teachings of Potts who describe hypercalcemic crises as resulting in coma or cardiac arrest. One of skill in the art would be motivated to provide an agent which would bind to PTHrP and decrease the binding of PTHrP to the PTH receptor because Potts teaches that it is the activation of the PTH receptor by PTHrP that is responsible for hypercalcemia. One of skill in the art would be motivated to combine the teachings of Potts with the teachings of Sato et al because the abstract of Sato et al states that the #23-57-137-1 antibody, which binds to PTHrP,



Art Unit: 1643

can be used in the treatment of hypercalcemia. One of skill in the art would readily conclude that the that #23-57-137-1 would act by inhibiting the binding of PTHrP and the PTH receptor. Without being able to inhibit the binding of the PTHrP to the PTH receptor, the antibody would not be effective in the treatment of hypercalcemia, and the effect would not be consistent with the teachings of Sato et al, that the antibody is useful in treating hypercalcemia and hypercalcemic crisis because both hypercalcemia and hypercalcemic crisis represent two related extremes resulting from the same physiological disorder. The difference between hypercalcemic crisis and hypercalcemia is only one of degree. In the case of the crisis the levels of calcium are such that cardiac arrest and coma are imminent. One of skill in the art would also be motivated to administered the claimed antibodies to a patient undergoing hypercalceimic crises in whom the conventional treatments listed in claim 35 have failed. One of skill in the art would want to try a new treatment which would act by a different molecular mechanism from that of the conventional treatments in order to prevent death from ensuing in the patient.

The rejections of claims 1, 4, 6, 9, 10, 12, 13-16, 19, 20 and 33-41 are rejected under 35 U.S.C. 103(a) as being unpatentable over the abstract of Sato et al (WO 9813388 and Potts (Diseases of the Parathyroid gland and other Hyper- and Hypocalcemic Disorders, In: Harrison's principles of Internal Medicine, 12th Edition, pages 1902-1915) as applied to claims 1, 6, 9, 10, 13, 16, 19, 20 33-36, 39, 40 and 41 above, and further in view of Schlom (In: Molecular foundations of Oncology, Samuel Broader, Ed, 1991, pages 95-134).

The combination of Sato et al and Potts renders obvious claims for the reasons set forth above. Claims 4 and 14 embody the methods of claims 1 and 13, respectively wherein the patient is administered at least one fragment of the humanized anti-PTHrP antibody. Claims 5 and 15 embody the method of claims 4 and 14, respectively wherein the fragment is chosen from at least one of Fab, scFV, F(ab')<sub>2</sub> and Fv. Neither the abstract of Sato et al nor Potts et al teach the administration of antibody fragments. Claims 37 and 38 embody the method of claim 3 wherein the patient is administered an antibody fragment.

Schlom teaches that F(ab')<sub>2</sub> or Fab' fragments also help reduce the HAMA response (page 119 second column, lines 16-17 under the heading "Single Chain Antigen Binding Proteins). Schlom

Art Unit: 1643

also teaches that scFv although comparable in binding affinity to Fab' have a more rapid plasma clearance than the Fab' fragment resulting in a greater tumor to tissue ratio. Schlom also points out that the small size of the scFv improves the capacity for penetration through the tumor mass. Schlom also points out that scFv are easier to make than F(ab')<sub>2</sub> of Fab' fragments. It would have been prima facie obvious to one of ordinary skill in the art at the time the claimed invention to use fragments of the #23-57-137-1 antibody in the treatment of hypercalcemic crises. One of ordinary skill in the art would have been motivated to do so with a reasonable expectation of success by the teachings of Schlom et al who point out that antibody fragments such as Fab' result in a greater tissue to tumor ratio and that scFv have a greater ability to penetrate tumor vasculature. The difference between hypercalcemic crisis and hypercalcemia is only one of degree. In the case of the crisis the levels of calcium are such that cardiac arrest and coma are imminent. One of skill in the art would also be motivated to administer the claimed antibodies to a patient undergoing hypercalcemic crises in whom the conventional treatments listed in claim 35 have failed. One of skill in the art would want to try a new treatment which would act by a different molecular mechanism from that of the conventional treatments in order to prevent death from ensuing in the patient.

The rejection of claims 1, 4, 6, 9, 10, 12, 13-16, 19, 20 and 33 under 35 U.S.C. 103(a) as being unpatentable over the abstract of Sato et al (WO 9813388) and Potts (Diseases of the Parathyroid Gland and Other Hyper- and Hypocalcemic Disorders, In: Harrison's principles of Internal Medicine, 12th Edition, pages 1902-1915) and Schlom (In: Molecular foundations of Oncology, Samuel Broader, Ed, 1991, pages 95-134).as applied to claims 1, 4, 6, 9, 10, 12, 13-16, 19, 20 and 33 above, and further in view of Gristina et al (US 5,681,565) is maintained for reasons of record. Claims 34-42 are rejected for the same reasons of record. Claims 10 and 20 embody the methods of claims 1 or 4, or claims 13 or 14, respectively, wherein the antibody is bound to a carrier. Claims 11, 21 and 42 specify that the carrier is PEG. Neither of the prior art references of the Sato et al abstract, nor Potts, nor Schlom teach antibodies bound to PEG as a carrier.

Gristina et al teach that antibodies can be administered in a cream or ointment carrier such as oleaginous bases or polyethylene glycol for in situ use (column 5, lines 3-21).

Art Unit: 1643

It would have been prima facie obvious to one of ordinary skill in the art at the time the claimed invention to use PEG as a carrier for the #23-57-137-1 antibody. One of ordinary skill in the art would have been motivated to do so with a reasonable expectation of success by the teachings of Grishina et al on the effectiveness of PEG as a carrier for in situ administration of antibodies. The difference between hypercalcemic crisis and hypercalcemia is only one of degree. In the case of the crisis the levels of calcium are such that cardiac arrest and coma are imminent. One of skill in the art would also be motivated to administer the claimed antibodies to a patient undergoing hypercalcemic crises in whom the conventional treatments listed in claim 35 have failed. One of skill in the art would want to try a new treatment which would act by a different molecular mechanism from that of the conventional treatments in order to prevent death from ensuing in the patient.

7. Claims 1, 4 and 6-16, 19-21 and 33 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 126-136 and 138 of copending Application No. 09/269,332 in view of Potts (Diseases of the Parathyroid gland and other Hyper- and Hypocalcemic Disorders, In: Harrison's principles of Internal Medicine, 12th Edition, pages 1902-1915) and Schlom (In: Molecular foundations of Oncology, Samuel Broader, Ed, 1991, pages 95-134).

Claims 126-136 and 138 of the '332 application teach the administration of a polypeptide comprising an L chain V region of a humanized antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NO:48-51 or 52-55.

Potts teaches that severe hypercalcemia, usually defined as 15 mg/dl or above is a medical emergency, and that coma or cardiac arrest can occur when serum calcium levels are at 15 to 18 mg/dl or higher.

Schlom teaches that F(ab')<sub>2</sub> or Fab' fragments also help reduce the HAMA response (page 119 second column, lines 16-17 under the heading "Single Chain Antigen Binding Proteins). Schlom also teaches that scFv although comparable in binding affinity to FAb' have a more rapid plasma clearance than the Fab' fragment resulting in a greater tumor to tissue ratio. Schlom also points out that the small size of the scFv improves the capacity for penetration

Art Unit: 1643

through the tumor mass.. Schlom also points out that scFv are easier to make than F9ab')<sup>2</sup> of Fab' fragments.

It would have been prima facie obvious to one of ordinary skill in the art at the time the claimed invention was made to treat a patient undergoing hypercalcemic crisis wherein said crises was manifest by coma or cardiac arrest by carrying out the methods of claims 126-136 and 138 in order to lower blood calcium to normal levels. One of ordinary skill in the art would have been motivated to do so with a reasonable expectation of success by the teachings of Potts regarding the risk of coma or cardiac arrest in individual having serum calcium levels of 15 mg/dl to 18 mg/ dl or higher. It would also be obvious to use a fragment of the antibody such as scFv for maximum penetration into the tumor vasculature.

It is noted that claims 126-136 and 138 do not specify the administration of a humanized #23-57-137-1 antibody. However, said antibody is included in the genus of antibodies upon which the '332 method claims depend. The Office does not have the facilities and resources to provide the factual evidence needed in order to establish that the product of the prior art does not possess the same material, structural and functional characteristics of the claimed product. In the absence of evidence to the contrary, the burden is on the applicant to prove that the claimed product is different from those taught by the prior art and to establish patentable differences. See *In re Best* 562F.2d 1252, 195 USPQ 430 (CCPA 1977) and *Ex parte Gray* 10 USPQ 2d 1922 (PTO Bd. Pat. App. & Int. 1989).

This is a provisional obviousness-type double patenting rejection.

14. Claims 1, 4 and 6-16, 19-21 and 33 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 126-136 and 138 of copending Application No. 09/269, and Potts (Diseases of the Parathyroid gland and other Hyper- and Hypocalcemic Disorders, In: Harrison's principles of Internal Medicine, 12th Edition, pages 1902-1915) and Schlom (In: Molecular foundations of Oncology, Samuel Broader, Ed, 1991, pages 95-134) as applied to claims 22-30 above and in further view of Gristina et al (US 5,681,565).

Gristina et al teach that antibodies can administered in a cream or ointment carrier such as oleaginous bases or polyethylene glycol for in situ use (column 5, lines 3-21).

Art Unit: 1643

It would have been prima facie obvious to one of ordinary skill in the art at the time the claimed invention to use PEG as a carrier for the antibodies in method claims 126-136 and 138 of application '322. One of ordinary skill in the art would have been motivated to do so with a reasonable expectation of success by the teachings of Grishina et al on the effectiveness of PEG as a carrier for in situ administration of antibodies. The difference between hypercalcemic crisis and hypercalcemia is only one of degree. In the case of the crisis the levels of calcium are such that cardiac arrest and coma are imminent. One of skill in the art would also be motivated to administer the claimed antibodies to a patient undergoing hypercalcemic crises in whom the conventional treatments listed in claim 35 have failed. One of skill in the art would want to try a new treatment which would act by a different molecular mechanism from that of the conventional treatments in order to prevent death from ensuing in the patient.

The examiner addressed the finality of the previous Office action in the advisory action, mailed March 31, 2005.

Applicants main argument against the instant rejections under 103(a) is that the references do not teach the administration of the claimed antibodies for the treatment of hypercalcemic crises which does not respond to the traditional agents which treat hypercalcemia. This has been considered but not found persuasive. One of skill in the art would be motivated to administer a new reagent which antagonizes a receptor known to be responsible for the hypercalcemia. One of skill in the art would have reasonable expectation of success as this treatment would eliminate the cause of the hypercalcemia rather than just treating the effects (i.e. physiological saline, which would simply dilute the blood and thereby temporarily decrease the calcium level).

Applicant has presented a declaration to aver that the administration of an antibody which inhibits the binding between PTHrP and a receptor thereof produces unexpected results, This has been considered but not found persuasive in light of the teachings of Sager et al on specifically inhibiting the PTHrP via an antagonistic antibody which inhibits the binding of PTHrP to the PTH receptor. The only teachings missing from Seger et al are the administration

Art Unit: 1643

of a humanized antibody rather than a murine antibody and this deficiency is made up by the teachings of Schlom on the advantages of humanized antibodies.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen A. Canella whose telephone number is (571)272-0828. The examiner can normally be reached on 11 am to 10 pm, except Wed, Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on (571)272-0832. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Karen A. Canella

7/11/2005

  
KAREN A. CANELLA PH.D  
PRIMARY EXAMINER